Sales of ChondroCelect, an autologous cell therapy for the repair of cartilage defects in the knee, increased by 21% to €3.1 million in the first nine months of 2013 from a year earlier, the developer, TiGenix NV reported. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News
